Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| NovoCure LtdNVCR · Entity 4494 | General Counsel | June 30, 2026 | July 01, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
NovoCure Ltd
Report date June 30, 2026 · Filed July 01, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 243,752 |
Reported balance
After 2026-06-30 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-06-30 · Grant · Acquired 1,299 · Balance 243,752 F1: The reporting person is voluntarily reporting the acquisition of shares of the issuer's ordinary shares pursuant to the 2025 NovoCure Limited Employee Share Purchase Plan ("ESPP"), for the ESPP purchase period of January 1, 2026 through June 30, 2026. This transaction is also exempt under Rule 16b-3(c). F2: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's ordinary shares on January 1, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: The reporting person is voluntarily reporting the acquisition of shares of the issuer's ordinary shares pursuant to the 2025 NovoCure Limited Employee Share Purchase Plan ("ESPP"), for the ESPP purchase period of January 1, 2026 through June 30, 2026. This transaction is also exempt under Rule 16b-3(c).
F2: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's ordinary shares on January 1, 2026.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 30, 2026 Filed Jul 1, 2026 20:30 UTC | NovoCure Ltd NVCR · Entity 4494 | GrantOrdinary Shares | 1,299 | $11.15 | $14,483.85 |
DisclosureSEC source: 0001917165-26-000006 · primarydocument.xml · nonDerivative · entry 1 Ben Arye Barak · CIK 0001917165 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 243,752 F1 · security: The reporting person is voluntarily reporting the acquisition of shares of the issuer's ordinary shares pursuant to the 2025 NovoCure Limited Employee Share Purchase Plan ("ESPP"), for the ESPP purchase period of January 1, 2026 through June 30, 2026. This transaction is also exempt under Rule 16b-3(c). F2 · price: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's ordinary shares on January 1, 2026. Read SEC document |
| March 03, 2026 Filed Mar 5, 2026 21:32 UTC | NovoCure Ltd NVCR · Entity 4494 | GrantStock Option (Right to Buy) · Derivative | 73,340 | $0.00 Strike: $13.30 | $0.00 |
DisclosureSEC source: 0001917165-26-000004 · primarydocument.xml · derivative · entry 2 Ben Arye Barak · CIK 0001917165 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 73,340 Underlying: Ordinary Shares · 73,340 shares Expires 2036-03-03 F2 · derivative.exercise_date: Options to buy ordinary shares that are scheduled to vest in equal parts on the first, second, third and fourth anniversary of the grant date, subject to the reporting person's continued employment through such date. Read SEC document |
| March 03, 2026 Filed Mar 5, 2026 21:32 UTC | NovoCure Ltd NVCR · Entity 4494 | GrantOrdinary Shares | 50,125 | $0.00 | $0.00 |
DisclosureSEC source: 0001917165-26-000004 · primarydocument.xml · nonDerivative · entry 1 Ben Arye Barak · CIK 0001917165 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 242,453 F1 · security: Represents restricted share units that are scheduled to vest in equal parts on the first, second and third anniversary of the grant date, subject to the reporting person's continued employment through such dates. Read SEC document |
| February 28, 2026 Filed Mar 3, 2026 21:09 UTC | NovoCure Ltd NVCR · Entity 4494 | GrantOrdinary Shares | 17,755 | $0.00 | $0.00 |
DisclosureSEC source: 0001917165-26-000003 · primarydocument.xml · nonDerivative · entry 1 Ben Arye Barak · CIK 0001917165 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 192,328 F1 · security: Represents vesting of performance-based restricted stock units. Read SEC document |
| December 31, 2025 Filed Jan 8, 2026 21:21 UTC | NovoCure Ltd NVCR · Entity 4494 | GrantOrdinary Shares | 108 | $10.99 | $1,186.92 |
DisclosureSEC source: 0001917165-26-000001 · primarydocument.xml · nonDerivative · entry 1 Ben Arye Barak · CIK 0001917165 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 174,573 F1 · security: The reporting person is reporting the acquisition of shares of the issuer's ordinary shares pursuant to the NovoCure Limited Employee Share Purchase Plan ("ESPP"), for the ESPP purchase period of July 1, 2025 through December 31, 2025. This transaction is also exempt under Rule 16b-3(c). F2 · price: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's ordinary shares on December 31, 2025. Read SEC document |
| June 30, 2025 Filed Jul 1, 2025 20:19 UTC | NovoCure Ltd NVCR · Entity 4494 | GrantOrdinary Shares | 769 | $15.13 | $11,634.97 |
DisclosureSEC source: 0001562180-25-005185 · primarydocument.xml · nonDerivative · entry 1 Ben Arye Barak · CIK 0001917165 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 174,465 F1 · security: The reporting person is voluntarily reporting the acquisition of shares of the issuer's ordinary shares pursuant to the 2025 NovoCure Limited Employee Share Purchase Plan ("ESPP"), for the ESPP purchase period of January 1, 2025 through June 30, 2025. This transaction is also exempt under Rule 16b-3(c). F2 · price: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's ordinary shares on June 30, 2025. Read SEC document |
| March 04, 2025 Filed Mar 6, 2025 21:42 UTC | NovoCure Ltd NVCR · Entity 4494 | GrantStock Options (Right to buy) · Derivative | 81,499 | $18.19 Strike: $18.19 | $1,482,466.81 |
DisclosureSEC source: 0001562180-25-002162 · primarydocument.xml · derivative · entry 2 Ben Arye Barak · CIK 0001917165 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 81,499 Underlying: Ordinary Shares · 81,499 shares Expires 2035-03-03 F2 · shares: Options to buy 81,499 ordinary shares will vest in equal installments on each of March 4, 2026, 2027, 2028 and 2029, subject to the reporting person's continued employment through such dates. Read SEC document |
| March 04, 2025 Filed Mar 6, 2025 21:42 UTC | NovoCure Ltd NVCR · Entity 4494 | GrantOrdinary Shares | 54,975 | $18.19 | $999,995.25 |
DisclosureSEC source: 0001562180-25-002162 · primarydocument.xml · nonDerivative · entry 1 Ben Arye Barak · CIK 0001917165 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 173,696 F1 · shares: Represents restricted share units that are scheduled to vest in equal installments on March 4, 2026, 2027 and 2028, subject to the reporting person's continued employment through such dates. Read SEC document |
| December 31, 2024 Filed Jan 3, 2025 21:04 UTC | NovoCure Ltd NVCR · Entity 4494 | GrantOrdinary Shares | 669 | $14.75 | $9,866.41 |
DisclosureSEC source: 0001562180-25-000067 · primarydocument.xml · nonDerivative · entry 1 Ben Arye Barak · CIK 0001917165 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 118,721 F1 · security: The reporting person is voluntarily reporting the acquisition of shares of the issuer's ordinary shares pursuant to the NovoCure Limited Employee Share Purchase Plan ("ESPP"), for the ESPP purchase period of July 1, 2024 through December 31, 2024. This transaction is also exempt under Rule 16b-3(c). F2 · price: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's ordinary shares on July 1, 2024. Read SEC document |
| June 28, 2024 Filed Aug 6, 2024 20:22 UTC | NovoCure Ltd NVCR · Entity 4494 | GrantOrdinary Shares | 930 | $12.24 | $11,383.20 |
DisclosureSEC source: 0001562180-24-006043 · primarydocument.xml · nonDerivative · entry 1 Ben Arye Barak · CIK 0001917165 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 118,052 F1 · security: The reporting person is voluntarily reporting the acquisition of shares of the issuer's ordinary shares pursuant to the NovoCure Limited Employee Share Purchase Plan ("ESPP"), for the ESPP purchase period of January 1, 2024 through June 30, 2024. This transaction is also exempt under Rule 16b-3(c). F2 · price: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's ordinary shares on June 28, 2024. Read SEC document |
| February 27, 2024 Filed Feb 29, 2024 21:30 UTC | NovoCure Ltd NVCR · Entity 4494 | GrantStock Options (Right to buy) · Derivative | 125,078 | $16.30 Strike: $16.30 | $2,038,771.40 |
DisclosureSEC source: 0001562180-24-001982 · primarydocument.xml · derivative · entry 3 Ben Arye Barak · CIK 0001917165 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 125,078 Underlying: Ordinary Shares · 125,078 shares Expires 2034-02-26 F4 · derivative.exercise_date: Options to buy 125,078 ordinary shares will vest in equal installments on each of February 27, 2025, 2026, 2027 and 2028, subject to the reporting person's continued employment through such dates. Read SEC document |
| February 27, 2024 Filed Feb 29, 2024 21:30 UTC | NovoCure Ltd NVCR · Entity 4494 | GrantOrdinary Shares | 81,799 | $16.30 | $1,333,323.70 |
DisclosureSEC source: 0001562180-24-001982 · primarydocument.xml · nonDerivative · entry 2 Ben Arye Barak · CIK 0001917165 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 117,122 F3 · shares: Represents restricted share units that are scheduled to vest in equal installments on February 27, 2025, 2026 and 2027, subject to the reporting person's continued employment through such dates. Read SEC document |
| December 31, 2023 Filed Feb 29, 2024 21:30 UTC | NovoCure Ltd NVCR · Entity 4494 | GrantOrdinary Shares | 128 | $12.69 | $1,624.32 |
DisclosureSEC source: 0001562180-24-001982 · primarydocument.xml · nonDerivative · entry 1 Ben Arye Barak · CIK 0001917165 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,323 F1 · security: The reporting person is voluntarily reporting the acquisition of shares of the issuer's ordinary shares pursuant to the NovoCure Limited Employee Share Purchase Plan ("ESPP"), for the ESPP purchase period of July 1, 2023 through December 31, 2023. This transaction is also exempt under Rule 16b-3(c). F2 · price: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's ordinary shares on December 31, 2023. Read SEC document |
| June 30, 2023 Filed Jul 6, 2023 20:13 UTC | NovoCure Ltd NVCR · Entity 4494 | GrantOrdinary Shares | 288 | $35.28 | $10,160.64 |
DisclosureSEC source: 0001562180-23-005758 · primarydocument.xml · nonDerivative · entry 1 Ben Arye Barak · CIK 0001917165 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,195 F1 · security: The reporting person is voluntarily reporting the acquisition of shares of the issuer's ordinary shares pursuant to the NovoCure Limited Employee Share Purchase Plan ("ESPP"), for the ESPP purchase period of January1, 2023 through June 30, 2023. This transaction is also exempt under Rule 16b-3(c). F2 · price: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's ordinary shares on June 30, 2023. Read SEC document |
| February 28, 2023 Filed Mar 2, 2023 21:56 UTC | NovoCure Ltd NVCR · Entity 4494 | GrantOrdinary Shares · Derivative | 29,531 | $76.97 Strike: $76.97 | $2,273,001.07 |
DisclosureSEC source: 0001645113-23-000028 · wf-form4_167779418753921.xml · derivative · entry 2 Ben Arye Barak · CIK 0001917165 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,531 Underlying: Ordinary Shares · 29,531 shares Expires 2033-02-27 F2 · derivative.exercise_date: Options to buy 29,531 ordinary shares will vest and become exercisable in equal installments on each of February 28, 2024, 2025, 2026 and 2027, subject to the reporting person's continued employment through such dates. Read SEC document |
| February 28, 2023 Filed Mar 2, 2023 21:56 UTC | NovoCure Ltd NVCR · Entity 4494 | GrantOrdinary Shares | 17,755 | $0.00 | $0.00 |
DisclosureSEC source: 0001645113-23-000028 · wf-form4_167779418753921.xml · nonDerivative · entry 1 Ben Arye Barak · CIK 0001917165 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,907 F1 · shares: Represents restricted share units that are scheduled to vest in equal installments on each of February 28, 2024, 2025 and 2026, subject to the reporting person's continued employment through such dates. Read SEC document |
| January 06, 2023 Filed Jan 10, 2023 21:20 UTC | NovoCure Ltd NVCR · Entity 4494 | GrantOrdinary Shares | 150 | $62.31 | $9,345.75 |
DisclosureSEC source: 0001645113-23-000015 · wf-form4_167338563438202.xml · nonDerivative · entry 1 Ben Arye Barak · CIK 0001917165 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,152 F1 · security: The reporting person is voluntarily reporting the acquisition of shares of the issuer's ordinary shares pursuant to the NovoCure Limited Employee Share Purchase Plan ("ESPP"), for the ESPP purchase period of July 1, 2022 through December 30, 2022. This transaction is also exempt under Rule 16b-3(c). F2 · price: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's ordinary shares on July 1, 2022. Read SEC document |
| July 05, 2022 Filed Jul 7, 2022 21:50 UTC | NovoCure Ltd NVCR · Entity 4494 | GrantOrdinary Shares | 144 | $59.08 | $8,506.80 |
DisclosureSEC source: 0001645113-22-000065 · wf-form4_165723060256540.xml · nonDerivative · entry 1 Ben Arye Barak · CIK 0001917165 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,002 F1 · security: The reporting person is voluntarily reporting the acquisition of shares of the issuer's ordinary shares pursuant to the NovoCure Limited Employee Share Purchase Plan ("ESPP"), for the ESPP purchase period of January 1, 2022 through June 30, 2022. This transaction is also exempt under Rule 16b-3(c). F2 · price: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's ordinary shares on June 30, 2022. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.